Notably, we estimated a similar effect size of APOE-ε4 on the risk of AD+LB– pathology (OR = 4.22) and on the risk of AD+LB+ co-pathology (OR = 4.24) versus AD–LB– pathology, suggesting that APOE-ε4 does not have a specific effect on the development of LB pathology in individuals with AD pathology. This evidence concerns the gene APOE and Alzheimer disease.